Pfizer and Roche, for example, both have oral GLP-1 treatments in development that could serve as direct competitors to Mercks global play with Hansoh
Semaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2
Plateaus on GLP-1 therapy happen for a few predictable reasons: your dose needs to go up, your body has adapted to your current medication, or there's a metabolic factor (thyroid, insulin resistance, cortisol) that bloodwork would reveal and guesswork won't
In fact, one clinical study of obese patients published in Nature Metabolism in 2023 found that those treated with liraglutide saw significant improvement in a range of associative learning tasks versus the placebo group
Some systematic reviews and meta-analyses have suggested potential benefits for glycaemic control and modest weight reduction
Pushpakumar SB, Kundu S, Sen U